Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Braz. dent. j ; 25(6): 538-542, Nov-Dec/2014. tab
Artículo en Inglés | LILACS | ID: lil-732251

RESUMEN

The aim of this study was to evaluate the degree of conversion (DC) and the cytotoxicity of photo-cured experimental resin composites containing 4-(N,N-dimethylamino)phenethyl alcohol (DMPOH) combined to the camphorquinone (CQ) compared with ethylamine benzoate (EDAB). The resin composites were mechanically blended using 35 wt% of an organic matrix and 65 wt% of filler loading. To this matrix was added 0.2 wt% of CQ and 0.2 wt% of one of the reducing agents tested. 5x1 mm samples (n=5) were previously submitted to DC measurement and then pre-immersed in complete culture medium without 10% (v/v) bovine serum for 1 h or 24 h at 37 °C in a humidifier incubator with 5% CO2 and 95% humidity to evaluate the cytotoxic effects of experimental resin composites using the MTT assay on immortalized human keratinocytes cells. As a result of absence of normal distribution, the statistical analysis was performed using the nonparametric Kruskal-Wallis to evaluate the cytotoxicity and one-way analysis of variance to evaluate the DC. For multiple comparisons, cytotoxicity statistical analyses were submitted to Student-Newman-Keuls and DC analysis to Tukey's HSD post-hoc test (=0.05). No significant differences were found between the DC of DMPOH (49.9%) and EDAB (50.7%). 1 h outcomes showed no significant difference of the cell viability between EDAB (99.26%), DMPOH (94.85%) and the control group (100%). After 24 h no significant difference were found between EDAB (48.44%) and DMPOH (38.06%), but significant difference was found compared with the control group (p>0.05). DMPOH presented similar DC and cytotoxicity compared with EDAB when associated with CQ.


O objetivo deste estudo foi avaliar o grau de conversão (GC) e a citotoxicidade de resinas compostas experimentais utilizando o álcool 4-(N,N-dimetilamino) fenil etílico (DMPOH) associado à canforoquinona (CQ) como sistema fotoiniciador (SF) comparado à versão comercial utilizando o benzoato de etilamina (EDAB). Para tanto, as resinas compostas experimentais foram mecanicamente misturadas utilizando (em peso): 35% de matriz orgânica e 65% em peso de partículas de carga. Posteriormente, foram adicionados 0,2% de CQ e 0,2% de um dos agentes redutores testados. Amostras de 5 x 1 mm (n=5) foram previamentes submetidas à análise de GC e posteriormente, esterilizadas e colocadas no meio de cultura completo sem soro fetal bovino estéril por 1 h ou 24 h a 37 °C em encubadora com 5% de CO2 and 95% de umidade para avaliar os efeitos citotóxicos das resinas compostas experimentais utilizando o método MTT emcélulas células humanas imortalizadas de queratinócitos. Os dados de citotoxicidade foram submetidos à análise estatística de Kruskal-Wallis e de GC à análise de variância com um fator. Em virtude da ausência de normalidade, a análise estatística da citotoxicidade foi realizada utilizando-se o teste não-paramétrico de Kruskal-Wallis. Para o GC, os dados foram submetidos à análise de variaância de 1 fator. Posteriormente para múltiplas comparações, os dados de citotoxicidade foram submetidos ao teste Student-Newman-Keuls e o GC ao teste de Tukey's HSD post-hoc (=0.05). Não foi observada diferença estatística entre o GC de DMPOH (49,9%) e EDAB (50,7%). Para os resultados de 1 h não houve diferença na viabilidade celular entre EDAB (99,26%), DMPOH (94,85%) e o grupo controle (100%). Após 24 h, nenhuma diferença estatística foi encontrada entre EDAB (48,44%) e DMPOH (38,06%), entretanto, diferença significativa foi encontrada em relação ao grupo controle (p>0,05). O DMPOH apresentou GC e citotoxicidade semelhante à EDAB quando associado à CQ.


Asunto(s)
Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Colon/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Administración Oral , Cisplatino/administración & dosificación , Esquema de Medicación , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Floxuridina/administración & dosificación , Neoplasias de la Vesícula Biliar/tratamiento farmacológico , Infusiones Intravenosas , Mitomicina , Mitomicinas/administración & dosificación , Neoplasias del Bazo/tratamiento farmacológico
2.
Braz. j. phys. ther. (Impr.) ; 18(6): 572-579, 09/01/2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-732350

RESUMEN

Background: Partial body weight support (BWS) systems have been broadly used with treadmills as a strategy for gait training of individuals with gait impairments. Considering that we usually walk on level ground and that BWS is achieved by altering the load on the plantar surface of the foot, it would be important to investigate some ground reaction force (GRF) parameters in healthy individuals walking on level ground with BWS to better implement rehabilitation protocols for individuals with gait impairments. Objective: To describe the effects of body weight unloading on GRF parameters as healthy young adults walked with BWS on level ground. Method: Eighteen healthy young adults (27±4 years old) walked on a walkway, with two force plates embedded in the middle of it, wearing a harness connected to a BWS system, with 0%, 15%, and 30% BWS. Vertical and horizontal peaks and vertical valley of GRF, weight acceptance and push-off rates, and impulse were calculated and compared across the three experimental conditions. Results: Overall, participants walked more slowly with the BWS system on level ground compared to their normal walking speed. As body weight unloading increased, the magnitude of the GRF forces decreased. Conversely, weight acceptance rate was similar among conditions. Conclusions: Different amounts of body weight unloading promote different outputs of GRF parameters, even with the same mean walk speed. The only parameter that was similar among the three experimental conditions was the weight acceptance rate. .


Asunto(s)
Anciano , Humanos , Masculino , Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias del Recto/patología , Adenocarcinoma/secundario , Tolerancia a Medicamentos , Floxuridina/administración & dosificación , Neoplasias Pulmonares/secundario , Mitomicina , Mitomicinas/administración & dosificación , Inducción de Remisión
4.
J Indian Med Assoc ; 1996 Feb; 94(2): 53-4, 57
Artículo en Inglés | IMSEAR | ID: sea-98180

RESUMEN

Results of 21 cases of squamous cell carcinoma of anal canal treated by continuous infusion of 5-fluorouracil 1000 mg/sqm for 4 days and mitomycin-C 15 mg/sqm on 1st day by i.v. route with concurrent external beam radiotherapy of 42 Gy from 1st day of chemotherapy were analysed. Out of 21 patients, 16(76.19%) achieved complete remission, 3 (14.28%) partial remission and 2 (9.52%) cases did not respond at all. On follow-up, 7 (33.33%) histopathological positive cases needed abdominoperineal resection with good recovery. After 2 years of follow-up 14 (66.67%) cases were free from the disease and 3 (14.28%) were alive with the disease. The median duration of follow-up was 36 months.


Asunto(s)
Adulto , Anciano , Antibióticos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias del Ano/tratamiento farmacológico , Carcinoma de Células Escamosas/tratamiento farmacológico , Quimioterapia Adyuvante , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Mitomicinas/administración & dosificación , Radioterapia Adyuvante , Inducción de Remisión , Análisis de Supervivencia
5.
Rev. bras. oftalmol ; 55(1): 13-5, jan. 1996. tab
Artículo en Portugués | LILACS | ID: lil-169901

RESUMEN

Trinta olhos de 30 pacientes foram submetidos a cirurgia combinada com o uso alternante de mitomicina nas concentraçöes de 0,5mg/ml e 1 mg/ml e tempo de exposiçäo de 5 minutos. Os resultados obtidos com a mitomicina na concentraçäo de 1 mg/ml foram melhores que os obtidos com mitomicina 0,5 mg/ml (66,6 por cento x 40 por cento de PIO menor ou igual a 16 mmHg sem medicaçäo), näo havendo complicaçöes em ambos os grupos


Asunto(s)
Humanos , Catarata/terapia , Terapia Combinada , Cirugía Filtrante , Glaucoma/terapia , Mitomicinas/administración & dosificación
6.
Rev. mex. oftalmol ; 69(6): 212-6, nov.-dic. 1995. ilus
Artículo en Español | LILACS | ID: lil-188205

RESUMEN

El exceso de filtración por falla valvular y más tardíamente por la formación de fibrosis ha motivado el diseño de nuevos instrumentos que alcancen mejor eficacia. El presente estudio trata de 14 ojos de 13 pacientes con glaucoma de difícil control, refractarios a cualquier tratamietno instituido. Se analiza este nuevo producto, valorando los resultados a pronto, mediano y largo plazo. Se observan las ventajas que se obtienen al implantar un mecanismo valvular y los resultados.


Asunto(s)
Niño , Adolescente , Adulto , Persona de Mediana Edad , Humanos , Masculino , Femenino , Humor Acuoso/fisiología , Procedimientos Quirúrgicos Oftalmológicos , Procedimientos Quirúrgicos Operativos , Glaucoma/cirugía , Oftalmopatías/terapia , Lentes Intraoculares/instrumentación , Mitomicinas/administración & dosificación , Antimetabolitos/farmacocinética , Síndrome de Sturge-Weber/cirugía
8.
Artículo en Inglés | IMSEAR | ID: sea-44537

RESUMEN

Fifteen patients with recurrent, metastatic, or residual cervical cancer post radiotherapy were treated by combined cis-platinum 40 mg/m2 IV and mitomycin-C 30 mg/m2 IV in day 1, repeated every 4 weeks for 3-5 cycles. The maintained therapy was performed by mitomycin-C 2 mg/day orally for 7 days, every 4 weeks for 6 cycles. Six of 15 patients (40%) showed complete remission and are alive without disease after a follow-up period of 5-41 months; 3 patients (20%) with partial remission are alive with disease after a follow-up period of 8-12.5 months; 6 patients (40%) with no remission expired with a survival time of 3-6 months. Severe anemia and leukopenia (grade 3-4) were seen in 26.66 per cent. Thrombocytopenia grade 4 was seen in 13.33 per cent of cases. Nausea and vomiting occurred in almost all patients. There were no problems with hepatotoxicity, nephrotoxicity, or ototoxicity.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Células Escamosas/tratamiento farmacológico , Cisplatino/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Mitomicina , Mitomicinas/administración & dosificación , Recurrencia Local de Neoplasia , Neoplasias del Cuello Uterino/tratamiento farmacológico
10.
Rev. bras. cancerol ; 32(3): 217-21, set. 1986. tab
Artículo en Portugués | LILACS | ID: lil-41237

RESUMEN

No período entre outubro de 1982 e agosto de 1984, 30 pacientes com carcinoma epidermóide do rinofaringe, estádios III (26,5%) e IV (73,5%), receberam uma combinaçäo de radioterapia (6.500 a 7.000cGy/7 a 7,5 semanas) e quimioterapia com 5-Fluorouracil (750mg/m*2, por infusäo contínua, dias 2 a 4), Mitomicina-C (10mg/m*2, endovenoso, dia 1) e Methotrexate (30mg/m*2, endovenoso, dia 1). A idade mediana foi de 40 anos e 20 pacientes eram do sexo masculino. Lindoepitelioma foi diagnosticado em 66,5% dos casos. O seguimento mínimo foi de 24 meses. As sobrevidas global e livre de doença em 48 meses foram de 49% e 35%, respectivamente. Dos 28 pacientes avaliáveis, 75% obtiveram resposta local completa. O índice de recidiva local foi de 9,5%. Falha à distância foi observada em 31% dos casos. O número de complicaçöes foi alta e inclui mucosite (grave em 52%), xerostomia, infecçäo (dois casos fatais de septicemia). Apesar da alta taxa de respostas completas obtidas, a pouca influência que isso exerceu na curva de sobrevida e o número elevado de complicaçöes nos levam a contra-indicar a terapia combinada como tratamento de rotina nesses tumores. Um estudo randomizado é necessário para estabelecer essa questäo


Asunto(s)
Adolescente , Adulto , Persona de Mediana Edad , Humanos , Masculino , Femenino , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/terapia , Neoplasias Nasofaríngeas/terapia , Fluorouracilo/administración & dosificación , Metotrexato/administración & dosificación , Mitomicinas/administración & dosificación
14.
Southeast Asian J Trop Med Public Health ; 1985 Dec; 16(4): 665-8
Artículo en Inglés | IMSEAR | ID: sea-32566

RESUMEN

Three hundred eligible patients with carcinoma of the cervix out of a total of 560, registered between July 1981 and June 1983 were randomized into receiving either radiotherapy alone or radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C4 mg. To date (22 Feb. 1985) patients have been evaluated for response to therapy at 3 months and 1 year from completion of treatment. Although both at 3 months and 1 year the combined modality treatment appears to be marginally better (68% and 71% at 3 months, 56% and 63% at 1 year), the long term results remain uncertain at present. Treatment by the addition of chemotherapy to radiation was however well tolerated with a few complications.


Asunto(s)
Adulto , Anciano , Bleomicina/administración & dosificación , Carcinoma/tratamiento farmacológico , Terapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Mitomicina , Mitomicinas/administración & dosificación , Estadificación de Neoplasias , Distribución Aleatoria , Neoplasias del Cuello Uterino/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA